Anjali Owens

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

Iacopo Olivotto, Artur Oręziak, Roberto Barriales‐Villa et al. · The Lancet · 2020 · 1.2K citations · Full text

Medicine, Cardiology, Pharmacotherapy +6

Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy

Milind Y. Desai, Anjali Owens, Jeffrey B. Geske et al. · Journal of the American College of Cardiology · 2022 · 353 citations · Full text

Medicine, Cardiology, Pharmacotherapy +12

Genetic Variants Associated With Cancer Therapy–Induced Cardiomyopathy

Pablo García‐Pavía, Yuri Kim, María Alejandra Restrepo-Córdoba et al. · Circulation · 2019 · 344 citations · Full text

Medicine, Genetics, Oncology +13

Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity

Andrew R. Harper, Anuj Goel, Christopher Grace et al. · Nature Genetics · 2021 · 339 citations · Full text

Medicine, Genetics, Molecular Genetics +14

Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy

Carolyn Y. Ho, Matthew E. Mealiffe, Richard G. Bach et al. · Journal of the American College of Cardiology · 2020 · 338 citations · Full text

Medicine, Cardiology, Pharmacology +14